These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30896536)

  • 1. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update.
    Ilmer M; Westphalen CB; Niess H; DʼHaese JG; Angele MK; Werner J; Renz BW
    Cancer J; 2019; 25(2):134-138. PubMed ID: 30896536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Optimal duration and timing of adjuvant chemotherapy after resection for pancreatic ductal adenocarcinoma].
    Strobel O; Büchler MW
    Chirurg; 2014 Jun; 85(6):543. PubMed ID: 24824005
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic ductal adenocarcinoma: is a cure possible?
    Ansari D; Andersson R
    Future Oncol; 2017 Apr; 13(10):863-865. PubMed ID: 28266248
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update.
    Yadavalli S; Yenugonda VM; Kesari S
    Cancer J; 2019; 25(2):139-146. PubMed ID: 30896537
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy: Targeting chromatin remodelling proteins to treat pancreatic cancer.
    Thomas H
    Nat Rev Gastroenterol Hepatol; 2015 Nov; 12(11):608. PubMed ID: 26441249
    [No Abstract]   [Full Text] [Related]  

  • 10. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.
    Chan E; Berlin J
    J Clin Oncol; 2014 Feb; 32(6):487-8. PubMed ID: 24419124
    [No Abstract]   [Full Text] [Related]  

  • 11. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression.
    Froeling FE; Kocher HM
    Gastroenterology; 2015 Apr; 148(4):849-50. PubMed ID: 25724458
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatic cancer: New insights into PDAC growth promotion via a BAG3-mediated paracrine loop.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):669. PubMed ID: 26577348
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells.
    Barcińska E; Wierzbicka J; Zauszkiewicz-Pawlak A; Jacewicz D; Dabrowska A; Inkielewicz-Stepniak I
    Oxid Med Cell Longev; 2018; 2018():8251961. PubMed ID: 30186549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma.
    Chung FH; Chiang YR; Tseng AL; Sung YC; Lu J; Huang MC; Ma N; Lee HC
    PLoS One; 2014; 9(1):e86299. PubMed ID: 24475102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model.
    Alves F; Borchers U; Padge B; Augustin H; Nebendahl K; Klöppel G; Tietze LF
    Cancer Lett; 2001 Apr; 165(2):161-70. PubMed ID: 11275365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
    Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthotopic model of human pancreatic ductal adenocarcinoma and cancer cachexia in nude mice.
    Jones-Bolin S; Ruggeri B
    Curr Protoc Pharmacol; 2007 Jun; Chapter 14():Unit 14.3. PubMed ID: 21948162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.